Introduction
Human diet is rich in a great variety of micronutritients with antioxidant properties. Dietary antioxidants (vitamins, minerals and phenolic compounds) as well as endogenous antioxidants may protect against oxidative stress. An increased dietary intake of antioxidants is associated with a reduced risk of some diseases. The consumption of low levels of antioxidants in the form of fruit and vegetables has been shown to more than double the incidence of certain cancers [1] [2] [3] [4] . Among these antioxidants, the extract from Aronia melanocarpa (Rosaceae) containing anthocyanidines, phenolic acids and quercetine glycosides [5] [6] [7] may play an important protective role. This extract containing active components may be present in human diet and is a good source of phenolic compounds. The extract from A. melanocarpa has antimutagenic activity and exhibits a distinct immunomodulatory activity in human lymphocyte cultures and in patients with breast cancer [8] . Moreover, this extract exerts multifunctional biological effects, including not only anti-cancer properties [7, 8] , but antioxidant [7, 9, 10] and anti-platelet properties as well [7, 9, 10] . Our preliminary results showed that the extract from A. melanocarpa reduced oxidative/nitrative stress in blood platelets in not only the healthy subject group, but also among breast cancer patients [6] . The concentration of the extract from A. melanocarpa used in our studies (50 µg/mL) was similar to that used in studies of other investigators [10] . Currently, there are no data in literature about any unwanted and toxic effects of A. melanocarpa fruits, juices and extracts. Because aronia extract is rich in anthocyanins, responsible for the inhibition of oxidative stress [7, 9, 10] , the aim of our present experiments was to study the effects of the extract from A. melanocarpa on the level of low-molecular-weight thiols (glutathione (GSH), cysteine (CSH), cysteinylglycine (CGSH) and homocysteine (HCSH)) determined by HPLC method in plasma from healthy volunteers, patients with invasive breast cancer and patients with benign breast diseases. The HPLC method used (with 2-chloro-1-methylquinolinium tetrafluoroborate -CMQT) is a fast, sensitive and selective method for the quantifications of picomoles of GSH and oxidized form of glutathione -GSSG even in plasma, where concentration of GSH is very low. The sensitivity of this method is even higher than methods using electrochemical detection. In these studies we also compared the action of the extract form berries of A. melanocarpa with effects of the wellknown commercial monomeric polyphenol, resveratrol (3, 4', 5-trihydroxystilbene).
Experimental Procedures

Chemicals
Resveratrol (trans-3,4',5-trihydroxystilbene) was purchased from Sigma. All other reagents were of analytical grade. Stock solution of resveratrol was made in 50% dimethylsulfoxide (DMSO) at the concentration of 5 mg/ml and kept frozen (-70˚C).
Plant material, extraction and isolation
The voucher specimen is deposited at the companyAgropharm Ltd, Poland (batch no. 020/2007k). The Aronia melanocarpa has been grown in Poland at large plantations to be used to produce phenolic-rich juices, jams and extracts. The material used for phenolic-rich extract production came from commercial production of aronia berries.
The HPLC separation of the phenolic-rich extract from berries of aronia revealed in the 254 nm profile the presence of a number of peaks (Figure 1) , and was described earlier [6] . Stock solutions of the extract of aronia (Aronox by Agropharm Ltd, Poland) was made in H 2 O at the concentration of 5 mg/mL; kept frozen (-70˚C) and was used for plasma experiments. 
Selection
Comparison group -patients with benign breast diseases
There were 11 women with benign breast diseases in the comparison group. Median age of patients was 46 years (range, 25-67 years; mean, 45.4 year; standard deviation, ±14.1). The breast pathology was diagnosed in left breast in 5 cases, and in right breast in 6 cases. Fibrocystic disease was diagnosed in 4 patients, fibroadenoma in 3 patients, fat necrosis in 2 patients, papilloma in 1 patient and typical ductal hyperplasia in 1 patient.
Isolation of plasma
Human blood from patients and healthy volunteers was collected into sodium citrate (5 mmol/L final concentration) and immediately centrifuged (3000 × g, 15 min) to get plasma. Blood samples from patients with breast cancer or benign breast diseases were taken before surgery, and breast cancer patients did not have preadjuvant therapy.
Some samples of plasma were incubated with the extract of A. melanocarpa or resveratrol (50 µg/mL, 5 min, 37˚C) and then kept frozen (-70˚C).
Determination of low-molecular-weight thiols in plasma
The classical technique HPLC has been used to analysis of thiols (glutathione, cysteine, cysteinylglycine and homocysteine) in plasma (from patients and healthy volunteers). HPLC analysis was performed with a Hewlett-Packard 1100 Series system according to Głowacki et al. [11] and Bald et al. [12] . The analytes (plasma) were derivatized with thiol-specific ultraviolet labeling reagent, 2-chloro-1-methylquinolinium tetrafluoroborate (CMQT), and separated from each other by reversed-phase high performance liquid chromatography with detection at 355 nm. Oxidized forms were converted to their thiol counterparts by reductive cleavage with sodium borohydride prior to the derivatization step. In order to circumvent the loss of reduced fraction of thiols due to oxidation during sample preparation, the derivatization reagent was added to whole blood immediately after collection and before separation of plasma. This method measures total thiols, reduced thiols and oxidized thiols, and is linear within the physiological and pathological ranges of thiols.
Statistical analyses
All the values in this study were expressed as mean ± SEM. In order to eliminate uncertain data, Grubbs test was performed. The statistically significant difference between the control group and patients was analyzed with the variance analysis (ANOVA test) in combination with Bonferroni correction. The statistical analysis of difference between the control plasma (without aronia extract) and plasma treated with aronia extract was done with paired Student's t-test using StatSoft Inc. "Statistica" v. 6.0.
Results
Using HPLC, we determined in human plasma the level of different thiols: glutathione, cysteine, cysteinylglycine and homocysteine. Our studies have shown that the level of total glutathione, cysteine and cysteinylglycine in plasma from patients with invasive breast cancer and patients with benign breast diseases was significantly lower than the level of these thiols in the control plasma obtained from healthy volunteers (Figure 2A, B and C) . The decrease of glutathione and cysteine reached about 50% of total values (Figure 2A and B) . The difference (for glutathione, cysteine, cysteinylglycine) between the control group and patients with benign breast diseases was statistically significant (ANOVA test -P<0.05). The same difference between the control group and patients with invasive breast cancer was observed (ANOVA test -P<0.05).
Moreover, we established that the levels of lowmolecular-weight thiols in reduced forms (GSH, CSH, CGSH) and in oxidized forms (GSSG, CSSC and CGSSGC) in plasma from patients with invasive breast cancer and patients with benign breast diseases were changed compared to healthy group (ANOVA test -P<0.05) ( Table 1) . Contrary, the level of homocysteine in plasma from patients with invasive breast cancer was significantly higher (about 15%) than in plasma obtained from healthy volunteers (ANOVA test -P<0.05) ( Figure 2D ).
We observed that in vitro the extract of A. melanocarpa (50 µg/mL, 5 min, 37˚C) reduced the differences of total low-molecular-weight thiols, thiols in reduced and oxidized forms in plasma from patients with invasive breast cancer and patients with benign breast diseases (Figure 2A and B, Table 1 ). the changes of the GSH/GSSG ratio and other thiols (cysteine and cysteinylglycine) in plasma from healthy group and patients in the presence of the extract from berries of A. melanocarpa (50 µg/mL, 5 min, 37˚C). The extract from berries of A. melanocarpa reduces the changes of the tested thiols ratio in plasma from patients with benign breast diseases (P<0.05) and in plasma from patients with invasive breast cancer (P<0.05) ( Table 2 ). The comparison effects of the aronia extract (50 µg/mL, 5 min, 37˚C) and resveratrol (50 µg/mL, Table 2 . Changes the GSH/GSSG ratio and other thiols (cysteine and cysteinylglycine) in plasma from the healthy group and patients with invasive breast cancer and patients with benign breast diseases in the presence of the extract from berries of A. melanocarpa (50 µg/mL, 5 min, 37˚C) and resveratrol (50 µg/mL, 5 min, 37˚C).
min, 37˚C) on the GSH/GSSG ratio and cysteine
or cysteinylglycine in plasma from tested groups is presented in Table 2 . We observed that the extract from A. melanocarpa has an even stronger effect than resveratrol alone in vitro (Table 2 ).
Discussion
Reactive oxygen species and damage caused by these species are implicated in the pathogenesis of a variety of diseases, including cancers. Although ROS may be generated as byproducts of aerobic metabolism, they are essential for various defense mechanisms in the cells or are involved in signalling processes. They can also cause oxidative damage to DNA, proteins and lipids. Moreover, during cancer therapy (radiotherapy or chemotherapy), ROS may be generated. The toxic side effects of chemotherapy may be associated also with damage to different molecules caused by ROS.
For the first time, our present results showed the changes of the total level of low-molecular-weight thiols, such as glutathione, cysteine and cysteinylglycine and their reduced and oxidized forms in plasma from patients with invasive breast cancer and patients with benign breast diseases. We observed that the thiol levels (GSH, CSH, CGSH) were lower in breast cancer patients than in control subjects (Figure 2A -C, Table 1 and 2). This is an interesting observation, but might be connected to the multiple various factors, including oxidative stress, because our earlier experiments showed the increased generation of superoxide anion radicals and oxidative/ nitrative modifications of proteins in blood platelets from breast cancer patients [6, 13] . On the other hand, we observed that the total level of homocysteine was significantly elevated in plasma of patients with invasive breast cancer ( Figure 2D ). This observation is consistent with the other earlier observations demonstrating that cultured breast cancer cells produce more homocysteine than normal cells [14] . Gatt et al. [15] showed also that hyperhomocysteinemia in women with advanced breast cancer exists. These observations may explain the high rate of venous thrombosis in women with metastatic breast malignancy, because increased concentration of homocysteine in the blood may be an independent risk factor for atherosclerotic disease, deep vein thrombosis and thromboembolism. Moreover, homocysteine induces changes in hemostasis, as well blood clotting as fibrynolysis [16] . Elevated level of homocysteine may disrupt functions of the vascular endothelium, changing the character of its surface from anticoagulant to procoagulant. Nishinaga et al. [17] have shown that homocysteine reduces antithrombin binding activity of endothelial cells. Hcys may alter properties of endothelial cells by impairing the production or bioavailability of vasoactive mediators, including nitric oxide, but also endothelin-1 [18, 19] .
Changes in glutathione content have been reported in several malignancies [20] [21] [22] . Kumar et al. [21] showed significantly lower levels of plasma glutathione in invasive cancer. In cancer patients the content of reduced glutathione in erythrocytes is also decreased. We suggest that decreased concentration of glutathione in plasma may promote oxidative stress in patients with invasive breast cancer and patients with benign breast diseases ( Figure 2A , Table 1 and 2), because glutathione is an important endogenous antioxidant and regulator of the redox status in plasma, and other tissues. Moreover, glutathione has other variety of physiologically important functions in defense and metabolism, including detoxication of electrophilic compounds, or synthesis and transport of biologically active, endogenous substances. Our present results showed that not only plasma glutathione, but also other thiols (cysteine and cysteinylglycine) are highly unstable and may be changed under oxidative stress in patients with invasive breast cancer and patients with benign breast diseases (Figure 2A -C, Table 1 and 2). Our results are consistent with the literature [23] [24] [25] . Rajneesh et al. [25] observed the significant increase of plasma lipid peroxidation and the decrease of antioxidant enzymes activity in plasma from breast cancer patients compared to controls.
Epidemiological and clinical studies suggest that diets rich in fruits and vegetables decrease the risk of premature mortality from major clinical conditions, including heart diseases and cancers. However, the data on using of antioxidant supplements during breast cancer are controversial. Review article of Greenlee et al. [26] showed that 22 articles did not support any conclusions regarding the effects of individual antioxidant supplements during conventional breast cancer treatment on toxicities, tumor response, recurrence, or survival, but a few studies suggested that antioxidants may decrease side effects associated with treatment, including vitamin E for hot flashes due to hormonal therapy and glutamine for oral mucositis during chemotherapy. Sharhar et al. [27] observed that poor antioxidant status (the low level of vitamin A, E and selenium in plasma) and high oxidative stress are associated with breast cancer risk in Malaysian women. However, many reports suggest anti-proliferative effects of chokeberries and/or chokeberry extracts against colon cancer on the basis of in vitro studies [28] [29] [30] and in one animal study [31] . Experiments of Yaneva et al. [32] indicate on the immunomodulatory activity of A. melanocarpa in combination with apple pectin in patients with breast cancer undergoing postoperative radiation therapy. Results of Lala et al. [31] show also the protective role of the extract from A. melanocarpa in colon carcinogenesis in vitro by multiple mechanism of action. In the present in vitro study, we analyzed the ability of the extract from A. melanocarpa (which may be integral part of human diet) to reduce the level of the low-molecular-weight thiols measured in plasma of patients with breast cancer, because the extract from A. melanocarpa reduces oxidation and nitration of platelet proteins from healthy subject group and breast cancer patients [6] . Moreover, in our earlier paper, we showed that the extract from A. melanocarpa added to blood platelets significantly reduced the production of superoxide anion radicals in platelets from breast cancer patients [13] .
Here, we have shown for the first time, that the extract from A. melanocarpa distinctly reduced differences in level of the low-molecular-weight thiols glutathione, cysteine and cysteinylglycine in the plasma of patients with invasive breast cancer and benign breast diseases (Figure 2A -C, Table 1 and 2). We have observed that an increase in free thiols is accompanied by a decrease in disulfides in plasma treated with aronia extract (in patients with benign breast diseases and patients with invasive breast cancer) (Figure 2A-C) . We may suggest that the free thiols are released from protein-bound thiols (disulfides) by the treatment of aronia (at model system in vitro), or in vivo aronia extract may induce the changes of activities of blood cell enzymes, which are involved in the metabolism of thiols [33] . We have also demonstrated that the extract from A. melanocarpa significantly decrease the level of homocysteine in plasma from patients with invasive breast cancer ( Figure 2D ). The obtained results are consistent with those in the literature [34] . We may suggest that polyphenols, which are presented in the tested extract, may induce an increase antioxidant capacity through enhancement of plasma superoxide dismutase or other enzymes. Moreover, our presented comparative studies on the effect of the extract from berries of A. melanocarpa and resveratrol on the level of the low-molecular-weight thiols in plasma of patients with invasive breast cancer, patients with benign breast diseases and the healthy subject group gave very similar results ( Table 2 ).
Our present results may provide a molecular basis for the well-documented oxidative stress (measuring not only by lipid peroxidation, but also by the redox status) in patients with breast cancer. However, further studies are needed evaluate the impact of pharmacologic treatment on modification of plasma proteins and thiols in breast cancer.
